In the search for treatment schemes of COVID-19, we start by examining the general weakness of coronaviruses and then identify approved drugs attacking that weakness . The approach, if successful, should identify drugs with a specific mechanism that is at least as effective as the best drugs proposed and are ready for clinical trials . All coronaviruses translate their non-structural proteins (∼16) in concatenation, resulting in a very large super-protein . Homo-harringtonine (HHT), which has been approved for the treatment of leukemia, blocks protein elongation very effectively . Hence, HHT can repress the replication of many coronaviruses at the nano-molar concentration . In two mouse models, HHT clears SARS-CoV-2 in 3 days, especially by nasal dripping of 40 ug per day . We also use dogs to confirm the safety of HHT delivered by nebulization . The nebulization scheme could be ready for large-scale applications at the onset of the next epidemics . For the current COVID-19, a clinical trial has been approved by the Ditan hospital of Beijing but could not be implemented for want of patients . The protocol is available to qualified medical facilities.